OREGON HEALTH SCIENCES UNIVERSITY



Professor of Medicine

SECTION HEAD, HEPATOLOGY, MEDICAL DIRECTOR OF LIVER TRANSPLANTATION

UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS, DIVISION OF GI/HEPATOLOGY

7TH FLOOR ANSCHUTZ OUTPATIENT PAVILION

1635 AURORA COURT, B154, AURORA, COLORADO 80045

CLINIC: (720) 848-2245 / FAX: (720) 848-2246

FACULTY POSITIONS AND TITLES

Professor of Medicine

University of Colorado Anschutz Medical Campus

July 2020 to present

Director of Hepatology

University of Colorado Hospital

January 2018 to present

Medical Director of Liver Transplantation

University of Colorado Hospital

February 2008 to present

Co- Director of Transplant and Hepatology Floor (AIP-1, 6th Floor)

University of Colorado Hospital

April 2018 to June 2019

Medical Director of Medicine Specialties Unit (AIP-2 9th Floor)

University of Colorado Hospital

February 2008 to April 2018

Associate Professor of Medicine

University of Colorado Denver, School of Medicine

July 2010 to present

Transplant Hepatology Fellowship Director

University of Colorado Denver, School of Medicine

April 2010 to June 2018

Assistant Fellowship Director

September 2007 to March 2010

Assistant Professor of Medicine

University of Colorado Denver, School of Medicine

July 2005 to June 2010

Assistant Professor of Medicine

Oregon Health & Science University

Portland, Oregon

August 2004 to June 2005

TRAINING

Gastroenterology Fellowship

Oregon Health & Science University

Portland, Oregon

July 2001 to June 2004

Transplant Hepatology Fellowship

Strong Memorial Hospital

Rochester, New York

June 2000 to June 2001

Internal Medicine Residency

Strong Memorial Hospital

Rochester, New York

June 1997 to June 2000

Hematology Categorical Certification Program

Department of Laboratory Medicine, University of Washington

Seattle, Washington

June 1992 to February 1993

EDUCATION

M.D., University of Washington School of Medicine

Seattle, Washington

August 1993 to June 1997

B.A., Political Science, University of Washington

Seattle, Washington

June 1988 to June 1992

WORK EXPERIENCE

Clinical Laboratory Technician

Clinical Nutrition Research Unit, Harborview Medical Center, University of Washington

February 1993 to August 1993

LICENCES AND CERTIFICATION

New Mexico State Medical License, No. 2015-0093, 2015-present

Colorado State Medical License, No. 43841, 2005 - present

Oregon State Medical License, No. 22948, 2001-2005

New York State Medical License, No. 212018, 1998-2001

Board Certified in Transplant Hepatology, November 2006; Recertification, November 2016

Board Certified in Gastroenterology, November 2004; Recertification, October 2014

Board Certified in Internal Medicine, October 2000; Recertification, October 2010

AWARDS

2020 Top Doc in Denver by 5280 Magazine

2019 Top Doc in Denver by 5280 Magazine

2017 Top Doc in Denver by 5280 Magazine

2016 University of Colorado Hospital, Medical Staff Award, Full Time Physician of the Year

2015 Top Doc in Denver by 5280 Magazine

2014 Top Doc in Denver by 5280 Magazine

2013 Top Doc in Denver by 5280 Magazine

2013 Rising Star Award – given by University of Colorado Department of Medicine to outstanding junior faculty who exemplify the department’s core values of excellence in research, clinical work, education, and community service

2012 Top Doc in Denver by 5280 Magazine

2009 Peak Performer Award –7th Annual Rocky Mountain Hospital Medicine Symposium

Recognizing the top inpatient providers across the region

October 5, 2009

2003-04 AASLD/Schering Advanced Hepatology Fellowship Award

Project: Hepatitis C Immunity in the Human Liver Transplant Model

Mentor: Hugo Rosen, MD

Raphael Dolin Resident Research Award

Dedication to Patient Care, Critical Scholarship and Teaching

June 2000

Excellence in Research

Western Student Medical Research Forum

February 1995

PUBLICATIONS

Jackson WE, Kriss MS, Burton JR, Nydam TL, Conzen KD, et al. Reply to “Living liver donors: A single-center experience.” Am J Transplant 18 June 2020;

Burton JR, Terrault NA, Goldberg DS, Bloom RD, Gilroy R, et al. Liver and kidney recipient selection of hepatitis C viremic donors: Meeting consensus report from the 2019 Controversies in Transplantation. Transplantation 2020;104:476-481.

Francis HL, Crismale JF, Schiano TD, Burton JR, Wieland AC, Kriss MS. Transjugular intrahepatic portosystemic shunt (TIPS) placement reduces sustained virologic response rates in decompensated hepatitis C cirrhotics treated with direct-acting antiviral agents: a multicenter, retrospective cohort study. Hepatology 2018;68(suppl):373A.

Kohli R, Chaturvedi S, Nguyen D, O’Meara M, Burton JR, Kriss MS. Post-traumatic stress disorder (PTSD) in adult liver transplant recipients: a pilot study. Hepatology 2018;68(Suppl):455A.

Kalra A, Burton JR, Forman LM. Pro: steroids can be withdrawn after transplant in recipient with autoimmune hepatitis. Liver Transpl 2018;24:1109-1112.

Rice J, Dodge, JL, Bambha KM, Bajaj JS, Reddy KR, Gralla J, Ganapathy D, Mitrani R, Reuter B, Paleski J, Acharya C, Shaw J, Burton JR, Biggins SW. Neutrophil-to-lymphocyte ratio associates independently with mortality in hospitalized patients with cirrhosis. Clin Gastroenterol Hepatol 2018;16:1186-1791.

MacBrayne CE, Castillo-Mancilla J, Burton JR, MaWhinney S, Wagner CB, et al. Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers. J Antimicrob Chemother 2018;73:156-159.

Dew MA, Butt Z, Liu Q, et al including Burton JR. Prevalence and predictors of patients-reported long-term mental and physical health after donation in the Adult-to-Adult Liver-Donor Liver Transplantation Cohort Study. Transplantation 2018;102:105-118.

Han S, Burton JR, Attwell A, Brauer B, Edmundowicz SA, et al. A comprehensive evaluation of dominant biliary strictures for malignancy in primary sclerosing cholangitis. Hepatology 2017;66(suppl):162A.

Rice J, Dodge, JL, Bajaj JS, Reddy R, Burton JR, et al. Admission neutrophil to lymphocyte ratio (NLR) is an independent predictor of mortality in hospitalized cirrhotic patients. Hepatology 2017;66(suppl):294A.

O’Leary JG, Fontana RJ, Brown K, Burton JR, Firpi-Morell R, et al. Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study. Transpl Int 2017;30:196-208.

Muething L, Burton JR. Malignancy and Primary Scleroising Chlangitis: Cholangiocarcinoma, Hepatocellular Carcinoma, and Gallbladder Carcinoma. In: Forman LF, eds. Primary Sclerosing Cholangitis: Current Understanding, Management and Future Developments. 1st ed. Switzerland: Springer International Publishing; 2017:13-27.

Wilkey BJ, Nanson R, Reece TB, Forman L, Burton JR, Messenger JC, et al. Tranfemoral Transcatheter Aortic Valve Replacement for Mixed Aortic Valve Disease in Child’s Class C Liver Disease Prior to Orthotopic Liver Transplantation: A Case Report. Semin Cardiothorac Vasc Anesth 2016;20:158-62.

Brown RS Jr. O’Leary JG, Reddy KR, Kuo A Morelli GJ, Burton JR, et al. Interferon-free Therapy for Genotype 1 Hepatitis C in Liver Transplant Recipients: Real-World Experience from the Hepatitis C Therapeutic Registry and Research Network. Liver Transpl 2016;22:24-33.

Helmke S, O’Leary J, Burton JR, Cookson M, Lauriski S, Trotter J, et al. Time course of hepatic gaft function improvement after ledipasvir/sofosbuvir treatment in liver transplant recipients with HCV and fibrosis or cirrhosis who achieved SVR. Am J Transpl 2016;16(Suppl):297A.

Kriss MS, Pigott C, Truesdale AE, Forman LM, Menard-Katcher P, Burton JR. Simulation-based training of Minnesota tube placement for GI fellows: utilization of a mastery learning model for low volume procedural training. Gastroenterol 2016;150(suppl):S201.

Nordstrom EM, Biggins SW, Gralla J, Rosen HR, Everson GT, Burton JR. Consenus Interferon for Recurrent Hepatitis C Infection in Nonresponders to Peginteferon and Ribavirin After Liver Transplanation. Exp Clin Transplant 2015;13:543-9.

Burton JR, O’Leary JG, Helmke S, Trotter JF, Denning J, Pang P, et al. HepQuant (HQ)-SHUNT improves in liver recipients with allograft fibrosis or cirrhosis during ledipasvir/sofosbuvir/ribavirin treatment for HCV. Transplantation 2015;99(suppl):O-57

Olthoff KM, Smith AR, Abecassis M, Baker, T, Edmond JC, Berg CL, Beil CA, Burton JR, et al. Defining Long-term Outcomes with Living Donor Liver Transplantation in North America. Ann Surg 2015:262:465-75.

Burton JR, O’Leary JG, Helmke S, Herman A, Cookson M, Lauriski, et al. Time course of hepatic improvement using HepQuant (HQ)-SHUNT function test during and after treatment with ledipasvir/sofosbuvir in liver transplant recipients with allograft fibrosis or cirrhosis and patients with decompensated cirrhosis who have not undergone transplant. J Hepatol 2015;62(suppl):S640-S641.

Verna EC, Saxena V, Burton JR, O'Leary JG, Dodge JL, Stravitz RT, et al. Telaprevir- and Boceprevir-Based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation. 2015;99:1644-51.

Wu LS, Rower JE, Burton JR, Anderson PL, Hammond KP, Baouchi-Mokrane F, et al. Population Pharmacokinetic Modeling of Plasma burtonjand Intracellular Ribavirin Concentrations in Patients with Chronic Hepatitis C Virus. Antimicrob Agents Chemother. 2015; 59;2179-88.

Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R Jr, Gordon F, Levitsky J, Terrault NA, Burton JR, Xie W, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Forns X. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014 Dec 18;371(25):2375-82. 

O’Leary JG, Burton JR, Helmke S, Herman N, Cookson M, Lauriski S, et al. Early improvement in the HepQuant (HQ)-Shunt function during treatment with ledipasvir/sofosbuvir in liver transplant recipients with allograft fibrosis or cirrhosis and patients with decompensated cirrhosis who have not undergone transplantation. Hepatology 2014;60(suppl):1134A.

Moorehead KJ, Burton JR, Everson GT, Zheng JH, Kerr BJ, Bushman LR, et al. Intrahepatic antiviral quantification in a patient undergoing orthotopic cadaveric liver transplantation. J Antimicrobial Chemother 2014 [Epub ahead of print].

Ladner DP, Dew MA, Forney S, Gillespie BW, Brown RS Jr, Merion RM, Freise CE, Hayashi PH, Hong JC Ashworth A, Berg CL, Burton JR, Shaked A, Butt Z. Long-term quality of life after liver donation in the adult to adult living donor liver transplantation cohort study (A2ALL). J Hepatol 2014;62:967-76.

Burton JR, O’Leary JG, Verna EC, Saxena V, Dodge JL, et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol 2014;61:508-14.

Stravitz RT, Levitsky J, Dodge JL, Saxena V, Burton JR, et al. Higher sustained virologic response (SVR-12) achievable in liver transplant (LT) recipients with hepatitis C (HCV) treated with protease inhibitor (PI) triple therapy (TT). Hepatology 2013;58(suppl):429A.

Ayres LE, Langness J, Tise S, Burton JR, Everson GT. Triple therapy for chronic hepatitis C virus (HCV) infection: a comparison of outcomes in patients with minimal versus advanced fibrosis. Hepatology 2013;58(suppl):1163A.

Kiser JJ, Burton JR, Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013;10:596-606.

Biggins SW, Trotter J, Gralla J, Burton JR, Bambha KM, et al. Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation. J Hepatol 2013;58:969-76.

Burton JR, Everson GT. Management of the transplant recipient with chronic hepatitis C. Clin Liver Dis 2013;17:73-91.

Verna EC, Burton JR, O’Leary JG, Lai JC, Saxena V, et al. A multicenter study of protease inhibitor-triple therapy in HCV –infected liver transplant recipients: report from the CRUSH-C group. J Hepatol 2013;58:S10.

Hammond KP, Wolfe P, Burton JR, Predhomme JA, Ellis CM, Ray ML, et al. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers. J Acquir Immune Defic Syndr 2013;62:67-73.

Burton JR, O’Leary JG, Verna EC, Lai JC, Everson GT, et al. A multicenter study of protease inhibitor-triple therapy in HCV-infected liver transplant recipients: report from the CRUSH-C group. Hepatology 2012;56(suppl):297A.

Murad DS, Kim WR, Harnois DM, Douglas DD, Burton JR, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012;143:88-98.

Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012;55:1620-8.

Burton JR, Everson GT. Initial experience with telaprevir for treating hepatitis c virus in liver recipients: virologic response, safety and tolerability. Am J Transpl 2012;12(suppl):LB01.

Harry BL, Smith ML, Burton JR, Dasari A, Eckhardt SG, Diamond JR. Medullary thyroid cancer and pseudocirrhosis: case report and literature review. Curr Oncol 2012;19:e36-41.

Burton JR. Timing of Referral for Liver Transplantation. In: Zaman A Ed. Managing the Complications of Cirrhosis: A Practical Approach. (1st Ed). Slack Inc., 2012.

Murad SD, Kim WR, Harnois DM, Douglas DD, Burton JR, et al. Effectiveness of neoadjuvant chrmoradiation followed by liver transplantation for hilar cholangiocarcinoma: a national experience. Hepatology 2011;54(suppl):494A.

Biggins S, Brocato MA, Trotter JF, Chang MF, Burton JR, et al. IL28B and IFN-gamma polymorphisms in HCV-infected liver transplant recpients: a large multicenter matched case-control analysis. Hepatology 2011;54(suppl):618A.

Kiser JJ, Burton JR, Roberts JL, Baouchi F, Wolfe P, et al. Intracellular ribavirin pharmacokinetics at first dose and steady state in persons with chronic HCV undergoing treatment with peginterferon alfa 2a and ribavirin. Hepatology 2011;54(suppl):820A.

Fortune BE, Martinez-Camacho A, Burton JR. Should living donor liver transplantation be an option for patients with hepatocellular carcinoma beyond Milan criteria? In: Jensen DM Ed. Controversies in Hepatology: The Experts Analyze Both Sides. (1st Ed). Slack Inc., 2011.

Benson AB, Burton JR, Austin GL, Biggins SW, Zimmerman MA, et al. Differential effects of plasm and red blood cell transfusion on acute lung injury and infection risk following liver transplantation. Liver Transpl 2011;17:149-58.

Shah RJ, Maximiliano S, Burton JR, Brauer BC. Biliary-enteric anastomotic stricturoplasty using overtube-assisted enteroscopy ERCP in patients with long libm surgical biliary bypass. Gastrointest Endosc 2011;74(suppl):Mo1461.

Berman K, Tandra S, Forssell K, Vuppalanch R, Burton JR, et al. Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol 2011;9:254-9.

Brocato M, Trotter JF, Forman L, Riccardi S, Burton JR, et al. Genetic variation of IL-28 associated with severity of HCV recurrence following liver transplantation. Hepatology 2010;52(suppl):875A.

Berman K, Tandra SR, Forssell K, Vuppalanchi R, Burton JR, et al. Incidence and predictors of 30 da hospital readmission among patients with advanced liver disease. Hepatology 2010;52(suppl):1247A.

Fortune BE, Rosen HR, Burton JR. Management of HCV Infection and Liver Transplantation. In: McDonald, Burroughs, Feagan and Fennerty Eds. Evidence-Based Gastroenterology and Hepatology (3rd Ed). Wiley-Blackwell, Oxford 2010.

Burton JR, Rosen HR, Martin P. Biological Principles and Clinical Issues Underlying Liver Transplantaiton for Virus-Induced End-Stage Liver Disease. In: Arias, Alter, Boyer, Cohen, Fausto, Shafritz and Wolkoff. Eds. The Liver: Biology and Pathobiology (5th Ed). John Wiley & Sons, Ltd. 2009.

Burton JR, Everson GT. NS5B-Polymerase Inhibitors. Clin Liv Disease 2009;13:453-65.

Burton JR, Klarquist J, Im K, Smyk-Pearson S, Golden-Mason L, Castelblanco N, Terrault NA, Rosen HR. Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy. J Hepatol 2008 Sep;49:329-338.

Smyk-Pearson S, Golden-Mason L, Klarquist J, Burton JR, Tester IA, Wang CC, Culbertson N, Vandenbark AA, Rosen HR. Functional suppression by FoxP3+CD4+CD25(high) regulatory T cells during acute hepatitis C virus infection. J Infect Dis 2008;197:46-57.

McCashland T, Lyden E, Adams L, McGuire B, Burton JR and the US Retransplant Study Group. Is retransplantation for HCV a bad idea? Results of a US multicenter retransplant study. Liver Transpl 2007;13:1246-53.

Rosen HR, Weston SJ, Im K, Yang, Burton JR, Erlich H, et al. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology 2007;46:350-8.

Arjal RR, Burton JR, Villamil F, Rosen HR. Review article: the treatment of hepatitis C virus recurrence after liver transplantation. Aliment Pharmacol Ther 2007;26:127-40.

Burton JR, Golden-Mason L, Rosen HR. Immunopathogenesis and Outcomes of Recurrent Hepatitis C. In: Gershwin ME, Vierling JM, Manns MP, eds. Liver Immunology: Principles and Practice. 1st ed. Totowa, New Jersey: Humana Press; 2007:459-470.

Burton JR, Suthat L, Lapidus J, Giannini E, Chalasani N, Zaman A. Validation of a multivariate model predicts presence and size of varices. J Clin Gastroenterol 2007;41:609-15.

Rosen HR, Burton JR. Recurrent Disease Following Liver Transplantation. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff’s Disease of the Liver. 10th ed. New York: Lippincott Williams & Wilkins; 2007: 1525-1544.

Burton JR, Golden-Mason L, Im K, Castelblanco N, Smyk-Pearson S, et al. Prospective analysis of FOXP3+CD4+CD25HI regulatory T cells in chronic HCV patients undergoing antiviral therapy: association with race and viral kinetics. Hepatology 2006;44(Suppl):314A.

Burton JR, Karlquist J, Im K, Smyk-Pearson S, Golden-Mason S, et al. Contraction of HCV-specific CD4+ Tcell responses in patients undergoing antiviral therapy irrespective of race and virologic outcome. Hepatology 2006;44(Suppl):327A.

Golden-Mason L, Burton JR, Castelblanco N, et al. Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence. Hepatology 2006;44:1098-1109.

Burton JR, Rosen HR. Acute rejection in HCV-infected liver transplant recipients: The great conundrum. Liver Transpl 2006;12:S38-S47.

Burton JR, Rosen HR. Diagnosis and management of allograft failure. Clin Liver Dis. 2006;10:407-35. Guest editor along with Dr. Hugo Rosen of this edition of Clinics in Liver Disease, Management of Difficult Problems in Hepatology.

Burton JR, Rosen HR. Treatment of HCV recurrence: Do the pretransplant rules apply? Liver Transpl 2006;12:1044-8.

Burton JR, Rosen HR. Liver retransplantation for hepatitis C virus recurrence: A survey of liver transplant programs in the United States. Clin Gastroenterol Hepatol 2005;3:700-704. Plenary Presentation at Digestive Disease Week May 2004.

Burton JR, Rosen HR. Retransplantation for hepatitis C: What do we really know? Liver Transpl 2004;10:1504-1506.

Burton JR. Is it time to change the way livers are allocated for patients with fulminant hepatic failure and acute graft failure after liver transplantation? Evidence-Based Gastroenterology 2004;5:88-89.

Burton JR, Shaw-Stiffel TA.

Use of Anti-HBc positive donors in recipients without evidence of hepatitis B infection: A survey of current practice at liver transplant programs in the United States. Liver Transpl 2003;9:837-842.

Burton JR, Lapidus J, Zaman A. A multivariate model predicts presence and size of varices: a validation study. Gastroenterol 2003;124(suppl)A733.

Burton JR, Katon R. Anterograde colonoscopy: Per oral diagnosis of colon cancer with an enteroscope in a man with history of jejunoileal bypass. Gastrointest Endosc. 2003;57(7):982-3.

Burton JR, Shaw-Stiffel TA. Viral Hepatitis. In: Reese, Betts B, Eds. A Practical Approach To Infectious Disease 5th Ed. Lippincott Williams & Wilkins, Philadelphia, Dec 2002.

Burton JR, Ryan C, Shaw-Stiffel TA. Liver transplantation in mushroom poisoning: Case report and review of literature. J Clin Gastroenterol 2002; 35:276-80.

Burton JR, Shaw-Stiffel TA. Gastrointestinal Problems in the Intensive Care Unit. In: Apostolakos JM, Papadakos PJ, Eds. The Intensive Care Manual. McGraw-Hill Publishing Co. April 2001.

Burton JR, Shaw-Stiffel TA. Effect of initial treatment of chronic hepatitis C with interferon alpha 2b and ribavirin on health-related quality of life. Gastroenterol 2000;118(suppl):A1427.

RESEARCH PRESENTATIONS AND INVITED LECTURES

Symptom Management in PSC. (Webinar) The Basics of Primary Sclerosing Cholangitis. PSC Partners, July 14, 2020.

Interpretation of LFTs: What Do You Need to Know? (Interactive Workshop). 66th Summer Family Medicine Review. YMCA Estes Park, Colorado, June 21, 2019.

Hepatitis Update 2019. 66th Summer Family Medicine Review. YMCA Estes Park, Colorado, June 21, 2019.

Answering Common Questions Regarding the Hospitalized Cirrhotic Patient. Society of Hospital Medicine Rocky Mountain Chapter Meeting. Denver Aquarium. May 15, 2019.

Hepatocellular Carcinoma: Screening, Diagnosis, MELD Exceptions and Post-transplant Recurrence. Multi-disciplinary Fellows Program. Anschutz Medical Campus. April 27, 2019.

Curbside Confidential: Answering the Most Common Liver Questions. 16th Annual Rocky Mountain Hospital Medicine Symposium. Anschutz Medical Campus, Aurora, Colorado, October 27, 2018.

Liver Transplantation: When to Refer and What are the Outcomes. Bridging Liver Disease to Primary Care – Live Course by Liver Health Connect. Anschutz Medical Campus, Aurora, Colorado, October 27, 2018.

Drug Abuse and the Liver – The Opioid Crisis. American Liver Foundation Rocky Mountain Division Ask the Experts Liver Education Program. Holy Comforter Episcopal Church, Broomfield, Colorado. October 6, 2018.

Update on HCV Infection. Rocky Mountain Update in GI/Hepatology 2018. Denver Tech Center, Colorado, June 9, 2018.

Review of Current Organ Allocation: MELD, Treating HCV and Share 35. American Liver Foundation Rocky Mountain Division Ask the Experts Liver Education Program. University of Colorado Hospital. May 5, 2018.

Cirrhosis and Its Complications. Nursing education lecture for nurses on Transplant Floor (AIP-1, 6th Floor), University of Colorado. February 27, 2018.

Liver Transplantation: When to Refer and What are the Ouctomes? and Immunosuppression for the Practicing Physician: What Do You Need to Know? 35th Annual Medical and Surgical Gastroenterology: A Multidisciplinary Approach, Vail, Colorado, January 29, 2018.

Treatment of HCV in the Transplant Setting. Rocky Mountain Highlights in GI/Hepatology 2017. Denver Tech Center, Colorado, June 17, 2017.

The Rebirth of LDLT in the Setting of the New Liver Allocation Scheme: Are the Indications the Same? – Perspective from a Hepatologist. Controversies in Transplantation, Breckenridge, Colorado, March 4, 2017.

Hepatitis C. American Liver Foundation Rocky Mountain Division Ask the Experts Liver Education Program. Double Tree by Hilton Denver. November 5, 2016.

Alcoholic Liver Disease. 63rd Fall Family Medicine Review. Anschutz Medical Campus, Aurora, Colorado. November 4, 2016.

Liver Your Way: You Pick the Topics you Want to Hear. 14th Annual Rocky Mountain Hospital Medicine Symposium. Denver, Colorado, October 18, 2016.

Alcoholic Liver Disease. 63rd Summer Family Medicine Review. YMCA Estes Park, Colorado. June 21, 2016.

Cirrhosis Overview. Medicine Specialty Unit Nursing Education Day, University of Colorado Hospital, February 26, 2016.

Indications For and Advances on Liver Transplantation. Cheyenne Regional Medical Center Grand Rounds, Cheyenne, Wyoming, January 16, 2016.

Diagnosis and Management of Hepatitis B & C. 62nd Fall Family Medicine Review. Anschutz Medical Campus, Aurora, Colorado, November 15, 2016.

Update on Liver Transplantation for the Colorado Gastroenterologist. Rocky Mountain Highlights in GI/Hepatology 2016, Denver Tech Center, June 11, 2016.

Treatment and Management of Chronic HCV Infection. Tuesday Afternoon Conference, Poudre Valley Hospital, Fort Collins, Colorado, March 8, 2016.

Evaluation and Treatment of Patients with Chronic Hepatitis C. Pancreatic and Biliary Education Conference. University of Colorado Cancer Center, August 12, 2015.

Diagnosis and management of Hepatitis B & C. 62nd Summer Family Medicine Review. YMCA Estes Park, Colorado, June 26, 2015.

Update on Treatment of HCV. Rocky Mountain Highlights in GI/Hepatology 2015, Denver, CO, June 6, 2015.

Management and Treatment of Chronic HCV Infection. Valley View Hospital Noon Conference, Glenwood Springs, Colorado, May 27, 2015.

Indications For and Advances in Liver Transplantation. Department of Medicine Grand Rounds, University of Colorado Hospital, May 13, 2015.

Liver Transplantation: Issues for the Colorado Gastroenterologist. The Rocky Mountain Gut Club, Denver, Colorado, December 4, 2014.

Perioperative Management of the Patient with Liver Disease. 12th Annual Hospital Medicine Symposium, Denver, Colorado, October, 10, 2014.

Liver Potpourri. Society of Hospital Medicine Rocky Mountain Chapter Meeting. Denver Aquarium. May 21, 2014.

Prevention and Treatment of Recurrent HCV Post-Transplant. Digestive Disease Week, Chicago, Illinois, May 6, 2014.

Indications for Liver Transplantation and Managing Pruritus and Sleep Disorders Related to Liver Disease. PSC Partner’s Seeking a Cure - 10th Annual Conference for Patients and Caregivers. April 26, 2014.

Verna EC, Burton JR, O’Leary JG, Lai JC, Saxena V, et al. A multicenter study of protease inhibitor-triple therapy in HCV-infected live transplant recipients: Report from the CRUSH-C group. J Hepatol 2013;58:S10-11. Presented at European Association Study of Liver Disease 2013, Amsterdam, The Netherlands, April 25, 2013.

Direct Acting Antivirals for HCV Post-Liver Transplant. Luncheon Workshop at American Transplant Congress 2013, Seattle Washington, May 19, 2013.

Treatment of Recurrent HCV after Liver Transplantation with Protease Inhibitor Based Triple Therapy. Department of Medicine Faculty Conference – Research and Innovation, Aurora, Colorado, April 18, 2013.

Management of Acute Liver Failure. Critical Care Conference for Pulmonary/Critical Care Fellows, January 11, 2013.

Treatment of Recurrent HCV Infection after Liver Transplantation: Past, Present and Future. Infectious Disease Grand Rounds, Aurora, Colorado, December 5, 2012.

Burton JR, O’Leary JG, Verna EC, Lai JC, Everson GT, Trotter JF, et al. A multicenter study of preotease inhibitor-triple therapy in HCV-infected liver transplant recipients: Report from the CRUSH-C group. Hepatology 2012;56 (Suppl): 211. Presented at Presidential Plenary: Viral Hepatitis at AASLD 2012, Boston, MA, November 13, 2012.

Caring for Patients with Hepatitis B&C. 59th Annual Family Medicine Review Course, Aurora, Colorado, November 8, 2012.

Dilemmas in the Management of the Decompensated Cirrhotic, 10th Annual Rocky Mountain Hospital Medicine Symposium. Denver, Colorado, September 27, 2012.

Caring for Patients with Hepatitis B&C, 59th Annual Family Medicine Review Course, Estes Park, Colorado, June 28, 2012.

Burton, JR, Everson GT. Initial Experience with Telaprevir for Treating Hepatitis C in Liver Recipients: Virologic Response, Safety, and Tolerability. Late Breaking Abstract, Oral Presentation. American Transplant Congress, Boston, MA, June 6, 2012.

Fortune BE, Sprague DR, Chascsa DM, Kirkland H, Forman LM, Biggins SW, and Burton, JR.. Incidence of early rejection between liver transplant recipients with related versus unrelated donor organs. Poster Presentation. Digestive Diseases Weekly 2012. San Diego, CA. May 19-22, 2012.

Management of Decompensated Liver Disease, 2012 Society of Hospital Medicine Annual Meeting, San Diego, California, April 3, 2012.

Case Presentation: An Unexpected Finding on Explant, Controversies in Liver Transplantation, Breckenridge, Colorado, March 3, 2012.

Overview of Immunosuppression. MEDS 8029 (medical student lecture), Anschutz Medical Campus, February 6, 2012.

Liver Transplantation 2012 – HCV Treatment, Hepatology Update, Best of AASLD 2011, Denver, Colorado, January 28, 2012.

Hepatitis C Virus Update, Advanced Concepts in Transplantation Seminar, Aurora, Colorado, November 17, 2011.

Approach to Acute Liver Disease, 9th Annual Rocky Mountain Hospital Medicine Symposium. Denver, Colorado, October 6, 2011.

Shah RJ, Smolkin M, Burton JR, Brauer BC. Biliary-enteric anastomotic stricturoplasty using overtube-assisted enteroscopy ERCP in patients with long limb surgical bypass. Poster presentation, Digestive Disease Week, Chicago, IL, May 7-10, 2011.

A Potpourri of Topics in Liver Transplantation. Pathology Resident Lecture, Anschutz Medical Campus, April 20, 2011.

Management of Acute Liver Failure. Critical Care Conference for Pulmonary/Critical Care Fellows, January 21, 2011.

Liver Transplant Evaluation. University of Colorado Department of Anesthesia Grand Rounds, January 10, 2010.

Dilemmas in the Management of the Decompensated Cirrhotic, 7th Annual Rocky Mountain Hospital Medicine Symposium. Denver, Colorado, October 6, 2009.

Liver Disease 101. Road to Transplant Seminar. Aurora, Colorado, June 26, 2009.

Yen R, Burton JR, Ringold DA, Chen YK, Fukami N, Brauer BC, Shah RJ. Severe recurrent hepatitis C following liver transplantation is associated with higher rates of anastomotic strictures. Poster Presentation, Digestive Disease Week, Chicago, IL, May 30-June 4, 2009.

Primary Sclerosing Cholangitis. 6th Annual Rocky Mountain Interventional Endoscopy Course: GI Nurses Course. Aurora, Colorado, February 11, 2009.

Hepatocellular Carcinoma: Clinical Decision Making. Advances in Transplantation Conference. Denver, Colorado, October 14, 2008.

Liver Transplantation in the MELD Era. Colorado Transplant Nurses Society Meeting. Denver, Colorado, October 8, 2008.

Who and When to Refer for Liver Transplantation in 2008. Valley View Hospital Grand Rounds. Glenwood Springs, Colorado, August 27, 2008.

Optimizing Treatment of Hepatitis C in 2008. Hep C Connection’s 2008 Colorado Viral Hepatitis Conference. Denver, Colorado, May 6, 2008

Recurrent HCV Following Liver Transplanation: Who Should Be Treated? American Hepato Pancreato Biliary Association 8th Annual Meeting. Fort Lauderdale, Florida, March 29, 2008.

Acute Rejection in HCV-Infected Liver Transplant Recipients: The Great Conundrum. Annual Meeting of the Swiss Transplantation Society. Interlaken, Switzerland, January 25, 2008.

Burton JR, Golden-Mason L, Im K, et al. Prospective analysis of CD4+CD25HiFoxP3+ regulatory T cells in chronic HCV patients undergoing antiviral therapy. Hepatology 2006 (Suppl);44:314A. Poster presentation at 2006 AASLD meeting, Boston, MA.

Burton JR, Klarquist J, Im K, et al. Contraction of HCV-specific CD4+ T cell responses in patients undergoing antiviral therapy irrespective of race and virologic outcome. Hepatology 2006 (Suppl);44:327A. Poster presentation at 2006 AASLD Meeting, Boston, MA.

Burton JR, Klarquist, J, Im KA, Belle SH, Rosen HR for Virahep-C Study Group. Stronger baseline HCV-specific immunity is associated with a higher likelihood of a sustained virological response to combination antiviral therapy of chronic hepatitis C (abstract). Poster of Distinction, Digestive Disease Week, Los Angeles, CA, May 21, 2006.

Hepatitis C Virus Immunity and Antiviral Therapy. American Gastroenterological Association Academic Skills Workshop. Phoenix, Arizona. February 25-27, 2005

Burton JR, Sonnenberg A, Rosen HR. Retransplantation for recurrent HCV in the MELD Era: Maximizing utility. Liver Transpl 2004 (suppl 2);10:S59-S64. Oral presentation at 2004 AASLD Parallel Session, Abstract #178.

Burton JR, Lapidus J, Zaman A, Liangpunsakul S, Chalasani N, Giannini EG. A multivariate model predicts presence and size of varices: A multicenter validation study. Hepatology 2004;40(Suppl):628A. Presented as poster at 2004 AASLD, abstract #1079.

Liver Retransplantation for HCV Recurrence: A Survey of Current Practice at Liver Transplant Programs in the US. Young Investigator’s Forum, Breckenridge, CO. March 4, 2004.

Burton JR, Lapidus J, Zaman A. A multivariate model predicts presence and size of varices: A validation study.

Poster presented at Digestive Disease Week, May 2003.

Schwartz J, Burton JR, Zaman A, Lambert G, Corless C, Rosen H, Flora K, Ham J, Orloff S. Cardiac and hepatic iron overload in patients with end stage liver disease. Hepatology 2002;36(suppl):121A. Poster presentation at Liver Meeting, Boston, MA, November 2002

Burton JR, Shaw-Stiffel TA. Effect of Initial Treatment of Chronic Hepatitis C with Interferon-(2b and Ribavirin on Health-Related Quality of Life. New York Chapter of American College of Physicians – American Society of Internal Medicine Upstate Associates Poster Competition. Syracuse, New York, October 1999.

Burton JR, Grable J. Carnitine Deficiency and Hyperammonemia Associated with Valproic Acid. First Place, New York Chapter of American College of Physicians – American Society of Internal Medicine Upstate Associates Poster Competition Syracuse, New York, October 1999

Burton JR, Labbe R. The Incidence of Supplementation of Hospitalized Patients with Low Plasma Vitamin C Concentrations. Western Student Medical Research Forum. Carmel, California, February 1995.

RESEARCH GRANTS/CONTRACTS

VX11-950-117 (REFRESH)– 1/1/2012-12/31/2014

A 2-part, open-label study of telaprevir in combination with peginterferon alfa-2a and ribavirin in subjects chronically infected with genotype 1 hepatitis C virus following liver transplantation

$91,146

Source: Vertex Pharmaceuticals

COMIRB 10-1195 10/7/2010 – 7/5/2013

Efficacy of neoadjuvant chemoradiotherapy followed by liver transplantation for hilar cholangiocarcinoma: a multi-center review, University of Colorado

$550.00

Source: Mayo Clinic

5U01DK062536-09 9/1/2010 – 12/31/2015 (Site PI 7/1/2013 – 12/31/2015)

Adult to adult living donor liver transplant cohort study (A2ALL)

$226,440

Source: NIH/NIDDK

P7977-2025 4/5/2012-4/5/2015

An open-label study to explore the clinical efficacy of GS-7977 with ribavirin administered pre-transplant in preventing hepatitis C virus (HCV) Recurrence post-transplant

$30,066

Source: Gilead Sciences

TMC435HPC2009 (Galaxay) 4/1/2014-1/1/2016

Phase 2 Open-label study in patients with recurrent genotype 1 hepatitis C post-orthotopic liver transplantat to explore the safety and efficacy of simeprevir and sofosbuvir with and without ribavirin.

$82,662.00

Source: Janseen Scientific Affairs, LLC

COMIRB 16-0820 9/2016-6/1/2018

The Estimated Cost of SVR in liver transplant recipients: comparison of treatment

Total costs $181,093

Source: UCSF/Gilead Pharmaceuticals

COMIRB 18-0559 (PRO-ACT Study) 10/31/2018 – present

Prevention of de novo HCV with antiviral HCV therapy post-liver and post-kidney transplant

Total costs to day: ~$15,000

Source: UCSF/Gilead Pharmaceuticals

COMMITTEES

American Associate for the Study of Liver Disease (AASLD) abstract reviewer for Liver Meeting and Digestive Disease Week, 2018-2022

Co-Chair, American Transplant Congress, Liver: Viral Hepatitis Abstract Selection 2017 and 2018

Member, AASLD, Practice Guidelines Committee, 2017-present

Chair, Liver Quality Assurance and Practice Improvement Committee, University of Colorado, 2017- present

Medical Advisory Committee, American Liver Foundation, Rocky Mountain Chapter, October 2016 – present.

Co-Director, Controversies in Transplantation Meeting, Breckenridge, CO, 2016-present

Co-Director, Rocky Mountain Highlights in GI/Hepatology, Denver, CO, 2015-2018

Adult to Adult Liver Donor Liver Transplantation Cohort Study, Publications and Presentations Committee, 2011 – 2013.

Chair, University of Colorado Liver Transplant Program, Weekly Selection Conference, 2008-present.

University of Colorado Gastroenterology Fellowship Committee, July 2005 – June 2018.

Abstract reviewer for International Liver Transplant Society 13th Annual International Congress, “Patient Selection and Organ Allocation”, January 2006

MEDICAL STUDENT TEACHING

Developed syllabus and give annual lectures to medical students on pathophysiology of the complications of cirrhosis, evaluation of abnormal liver enzymes with case studies as well as group leader in small groups.

1. Digestive, Endocrine and Metabolic Systems (DEMS) Block (Course #IDPT 6002) Lectures 2006-2018; 150 students

- Complications of Cirrhosis (2 hours)

- Abnormal Liver Chemistries (2 hours)

2. DEMS Block small group leader, 2006-2018; 15-20 students

- Hepatitis & Acute Liver Injury (2 hours)

- Cirrhosis & Chronic Liver Injury (2 hours)

3. Clinical Laboratory Medicine elective (Course #IDPT 8030; formerly PATH 8001) Lecture 2011-2018; 20-25 students

- Abnormal Liver Enzymes (1 hour)

MANUSCRIPT REVIEWER

2015 – Top 25 Reviewers for Liver Transplantation.

Invited Journal Reviewer: Hepatology, American Journal of Transplantation, Liver Transplantation, American Journal of Gastroenterology, Clinical Journal of Gastroenterology and Alimentary Pharmacology & Therapeutics.

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download